N- (1- (1-benzyl - 4-phenyl-1H-imidazol-2-YL) - 2,2-dymethylpropyl) benzamide derivatives and related compounds as kinesin spindle protein (KSP) inhibitors for the treatment of cancer
Details for Australian Patent Application No. 2005258135 (hide)
International Classifications
Event Publications
1 February 2007 PCT application entered the National Phase
PCT publication WO2006/002236 Priority application(s): WO2006/002236
8 January 2009 Alteration of Name
The name of the applicant has been altered to Novartis Vaccines & Diagnostics, Inc.
22 September 2011 Application Accepted
Published as AU-B-2005258135
19 January 2012 Standard Patent Sealed
Legal
The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.
Next and Previous Patents/Applications
2005258137-Validating client-receivers
2005258134-Bumper having separate energy absorber and fascia support
IP Reporting Samples
Customised IP Reporting
IP Insider for IP Professionals
IP Monitor Professional
- Editable Word format reports
- For IP Professionals
- Multiuser